Skip to main content
AI Market Summary
Loading market intelligence...

Axonics, Inc. (AXNX) Stock Forecast 2025 - AI Price Prediction & Analysis


Axonics, Inc. (AXNX) AI Stock Price Forecast & Investment Analysis

Axonics, Inc. Stock Price Chart and Technical Analysis

Loading Axonics, Inc. interactive price chart and technical analysis...

Axonics, Inc. (AXNX) - Comprehensive Stock Analysis & Investment Research

Deep dive into Axonics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Axonics, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Axonics, Inc.: Axonics, Inc. operates in the Industrial Applications and Services sector, establishing it as a mid-cap growth opportunity.

Axonics, Inc. (Stock Symbol: AXNX) is a leading company in the Industrial Applications and Services sector , specifically operating within the Surgical & Medical Instruments & Apparatus industry.

The organization employs approximately 353 professionals worldwide .

The company has established itself as a growing mid-cap opportunity with strong fundamentals.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Axonics, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Axonics, Inc.: With $619M in annual revenue and 1.6% net margin, the company demonstrates developing profitability.

Annual Revenue: $619 million generating a 1.6% net profit margin .

Market Capitalization: $3628 million - Classified as a mid-cap growth stock with balanced risk-reward profile.

Return on Equity (ROE): -20.2% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Axonics, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Axonics, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Axonics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Axonics, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Axonics, Inc.: Market positioning analysis based on available financial and operational metrics.

Axonics, Inc. strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace, establishing itself as a promising mid-cap growth opportunity with strong fundamentals and expanding market share .

The company maintains a healthy 50.1% gross margin, indicating strong pricing power and operational efficiency.

Axonics, Inc. (AXNX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Axonics, Inc. stock analysis.

Loading Axonics, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Axonics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Axonics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Axonics, Inc.: With a P/E ratio of -1155.49, the market sees the stock as potentially undervalued.

P/E Ratio -1155.49x
P/B Ratio 5.46x
Market Cap $3628M
EPS $-0.11
Book Value/Share $13.00
Revenue/Share $8.01
FCF/Share $-2.46
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Axonics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Axonics, Inc.: An ROE of -20.2% indicates room for improvement in shareholder value creation.

ROE -20.2%
ROA -16.5%
ROIC -17.2%
Gross Margin 50.1%
Operating Margin -2.4%
Net Margin 1.6%
EBT Margin -41.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Axonics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Axonics, Inc.: A current ratio of 12.05 indicates strong liquidity.

Current Ratio 12.05x
Quick Ratio 9.43x
D/E Ratio 0.02x
Financial Leverage 1.13x
Interest Coverage -11.8x
Working Capital $282M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Axonics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Axonics, Inc.: Free cash flow of $-33M indicates cash challenges that need attention.

Operating Cash Flow $-31M
Free Cash Flow $-33M
Capital Spending $-2M
FCF/Sales -17.1%
CapEx/Sales 1.3%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Axonics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Axonics, Inc.: An asset turnover of 0.40x suggests room for improvement in asset utilization.

Asset Turnover 0.40x
Receivables Turnover 7.9x
Inventory Turnover 1.0x
Fixed Assets Turnover 30.0x
Days Sales Outstanding 46 days
Days Inventory 369 days
Payables Period 61 days
Cash Conversion Cycle 355 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Axonics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Axonics, Inc.: With annual revenue of $619M, Axonics, Inc. demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $619M
Operating Income $-20M
Net Income $10M
R&D Expense $47M
SG&A Expense $79M
Cost of Goods Sold $101M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 59%
Cash & Short-term Investments 41%
Total Liabilities 12%
Short-term Debt 0%
Accounts Receivable 5%
Inventory 12%
Dividend & Shareholder Information
Shares Outstanding 51M
Growth Metrics (YoY)
EPS Growth -0.2%

Latest Axonics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Axonics, Inc. (AXNX) stock price and investment outlook.

, source: Seeking Alpha

Ladies and gentlemen, thank you for standing by. Welcome to the Axonics Third Quarter 2023 Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

, source: Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two ...

, source: Seeking Alpha

Thank you for standing by and welcome to the Axonics' First Quarter 2023 Results Conference Call. At this time, all participants are in listen-only mode. After the speakers' presentation, there will ...

Axonics, Inc. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of Axonics, Inc. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ADGM Unlock Forecast - 30 Days FREE Trial $15M x 1.6x
AEMD Unlock Forecast - 30 Days FREE Trial $9M -0.1x 1.6x
ALUR Unlock Forecast - 30 Days FREE Trial $13M -0.4x -0.3x
AMIX Unlock Forecast - 30 Days FREE Trial $2M x 0.3x
ANGO Unlock Forecast - 30 Days FREE Trial $545M -1.4x 3.0x
ANIK Unlock Forecast - 30 Days FREE Trial $138M -4.3x 0.9x
AORT Unlock Forecast - 30 Days FREE Trial $2075M -198.2x 4.7x
APYX Unlock Forecast - 30 Days FREE Trial $146M -3.5x 25.0x
ARAY Unlock Forecast - 30 Days FREE Trial $120M -9.9x 1.9x
ATEC Unlock Forecast - 30 Days FREE Trial $2981M -7.4x 259.1x
ATRC Unlock Forecast - 30 Days FREE Trial $2107M -39.6x 4.4x
AVHHL Unlock Forecast - 30 Days FREE Trial $24M x x
BAX Unlock Forecast - 30 Days FREE Trial $9843M -94.9x 1.4x
BBNX Unlock Forecast - 30 Days FREE Trial $1309M x 4.4x
BDX Unlock Forecast - 30 Days FREE Trial $57959M 34.5x 2.3x
BEAT Unlock Forecast - 30 Days FREE Trial $79M -5.7x 194.5x
BJDX Unlock Forecast - 30 Days FREE Trial $2M -0.5x 0.5x
BSX Unlock Forecast - 30 Days FREE Trial $138315M 49.4x 5.9x
BTCY Unlock Forecast - 30 Days FREE Trial $9M -2.7x -0.1x
BVS Unlock Forecast - 30 Days FREE Trial $519M 66.4x 3.1x
CARL Unlock Forecast - 30 Days FREE Trial $130M x 1.2x
CERS Unlock Forecast - 30 Days FREE Trial $414M -13.8x 6.7x
CLPT Unlock Forecast - 30 Days FREE Trial $361M -23.5x 22.8x
CODX Unlock Forecast - 30 Days FREE Trial $16M -0.7x 0.4x
CTSO Unlock Forecast - 30 Days FREE Trial $43M -1.8x 4.8x
CVRX Unlock Forecast - 30 Days FREE Trial $221M -5.5x 4.6x
DCTH Unlock Forecast - 30 Days FREE Trial $366M 305.6x 3.2x
DHAI Unlock Forecast - 30 Days FREE Trial $0M x -0.3x
DRIO Unlock Forecast - 30 Days FREE Trial $552M 0.6x 7.4x
DRTS Unlock Forecast - 30 Days FREE Trial $429M x 5.0x
DXCM Unlock Forecast - 30 Days FREE Trial $26114M 36.2x 9.6x
DYNT Unlock Forecast - 30 Days FREE Trial $1M -0.2x 0.2x
EBRCZ Unlock Forecast - 30 Days FREE Trial $272M x 7.0x
ECIA Unlock Forecast - 30 Days FREE Trial $3M x 1.7x
EMBC Unlock Forecast - 30 Days FREE Trial $690M 7.2x -0.8x
EMED Unlock Forecast - 30 Days FREE Trial $0M x x
FEMY Unlock Forecast - 30 Days FREE Trial $41M -1.4x 8.9x
FOFA Unlock Forecast - 30 Days FREE Trial $8M x 10.0x
GCTK Unlock Forecast - 30 Days FREE Trial $5M 0.9x 1.9x
GIPL Unlock Forecast - 30 Days FREE Trial $5M x 25.8x
GKOS Unlock Forecast - 30 Days FREE Trial $6248M -46.3x 8.1x
GMED Unlock Forecast - 30 Days FREE Trial $11897M 28.1x 2.7x
GUTS Unlock Forecast - 30 Days FREE Trial $122M x 13.8x
HAE Unlock Forecast - 30 Days FREE Trial $3903M 23.2x 4.6x
HRGN Unlock Forecast - 30 Days FREE Trial $35M x 22.3x
IART Unlock Forecast - 30 Days FREE Trial $1028M 200.2x 1.0x
ICCM Unlock Forecast - 30 Days FREE Trial $39M x 13.5x
ICU Unlock Forecast - 30 Days FREE Trial $11M -1.1x 1.0x
ICUI Unlock Forecast - 30 Days FREE Trial $3664M -49.8x 1.7x
IDXG Unlock Forecast - 30 Days FREE Trial $6M 1.3x -0.9x
IINN Unlock Forecast - 30 Days FREE Trial $28M x 6.5x
IINNW Unlock Forecast - 30 Days FREE Trial $6M x 1.5x
INBS Unlock Forecast - 30 Days FREE Trial $5M -0.3x 1.4x
INFU Unlock Forecast - 30 Days FREE Trial $188M 34.0x 3.4x
INSP Unlock Forecast - 30 Days FREE Trial $3797M 85.2x 5.7x
IRMD Unlock Forecast - 30 Days FREE Trial $1224M 57.8x 12.5x
IRTC Unlock Forecast - 30 Days FREE Trial $5437M -20.2x 44.6x
KIDS Unlock Forecast - 30 Days FREE Trial $412M -20.7x 1.2x
KMTS Unlock Forecast - 30 Days FREE Trial $1344M x x
KRMD Unlock Forecast - 30 Days FREE Trial $268M -19.8x 16.3x
LMAT Unlock Forecast - 30 Days FREE Trial $1925M 36.1x 5.1x
LNSR Unlock Forecast - 30 Days FREE Trial $137M -6.7x -7.0x
LUCD Unlock Forecast - 30 Days FREE Trial $152M -0.6x 5.9x
LUNG Unlock Forecast - 30 Days FREE Trial $104M -4.3x 1.7x
LYRA Unlock Forecast - 30 Days FREE Trial $6M -0.1x 4.6x
MBOT Unlock Forecast - 30 Days FREE Trial $93M -1.3x 1.2x
MCAG Unlock Forecast - 30 Days FREE Trial $34M x -9.6x
MCAGU Unlock Forecast - 30 Days FREE Trial $31M x -9.9x
MDAI Unlock Forecast - 30 Days FREE Trial $44M -1.3x -42.3x
MDNC Unlock Forecast - 30 Days FREE Trial $59M 26.2x 12.2x
MDXG Unlock Forecast - 30 Days FREE Trial $1069M 26.2x 4.5x
MGRM Unlock Forecast - 30 Days FREE Trial $217M -10.7x 25.1x
MHUA Unlock Forecast - 30 Days FREE Trial $216M x 1.3x
MMM Unlock Forecast - 30 Days FREE Trial $89724M 26.4x 19.4x
MMSI Unlock Forecast - 30 Days FREE Trial $5140M 43.4x 3.4x
MODD Unlock Forecast - 30 Days FREE Trial $21M -2.1x 2.4x
NEPH Unlock Forecast - 30 Days FREE Trial $53M 36.0x 6.4x
NMTC Unlock Forecast - 30 Days FREE Trial $24M -1.7x 3.0x
NPCE Unlock Forecast - 30 Days FREE Trial $539M -10.4x 29.1x
NSPR Unlock Forecast - 30 Days FREE Trial $82M -4.3x 1.3x
NUMD Unlock Forecast - 30 Days FREE Trial $2M x x
NVCR Unlock Forecast - 30 Days FREE Trial $1492M -20.8x 4.4x
NXGL Unlock Forecast - 30 Days FREE Trial $14M -6.8x 2.6x
OBIO Unlock Forecast - 30 Days FREE Trial $255M -3.4x 2.6x
ODYY Unlock Forecast - 30 Days FREE Trial $4M x x
OFIX Unlock Forecast - 30 Days FREE Trial $612M -5.8x 1.4x
OSRH Unlock Forecast - 30 Days FREE Trial $15M x 0.2x
OSUR Unlock Forecast - 30 Days FREE Trial $180M 17.1x 0.5x
PAVM Unlock Forecast - 30 Days FREE Trial $8M 2.5x 0.2x
PDEX Unlock Forecast - 30 Days FREE Trial $142M 12.6x 3.4x
PEN Unlock Forecast - 30 Days FREE Trial $12247M 74.7x 9.0x
PETV Unlock Forecast - 30 Days FREE Trial $37M -1.4x 8.8x
PLRZ Unlock Forecast - 30 Days FREE Trial $74M x 4.0x
PLSE Unlock Forecast - 30 Days FREE Trial $965M -2.6x 10.4x
PMI Unlock Forecast - 30 Days FREE Trial $22M x 2.8x
PODD Unlock Forecast - 30 Days FREE Trial $21377M 86.8x 15.5x
PRCT Unlock Forecast - 30 Days FREE Trial $2011M -45.4x 5.3x
PROF Unlock Forecast - 30 Days FREE Trial $221M x 6.9x
PSTV Unlock Forecast - 30 Days FREE Trial $17M -0.3x 3.4x
PYPD Unlock Forecast - 30 Days FREE Trial $24M x 1.2x
RCEL Unlock Forecast - 30 Days FREE Trial $106M -5.0x -29.9x
RDGL Unlock Forecast - 30 Days FREE Trial $33M x 15.0x
RMD Unlock Forecast - 30 Days FREE Trial $36816M 25.6x 6.0x
RSMDF Unlock Forecast - 30 Days FREE Trial $3977M 2.8x 0.7x
RTGN Unlock Forecast - 30 Days FREE Trial $60M x x
RVP Unlock Forecast - 30 Days FREE Trial $25M -0.9x 0.3x
SGHT Unlock Forecast - 30 Days FREE Trial $425M -3.7x 6.6x
SIBN Unlock Forecast - 30 Days FREE Trial $804M -14.3x 4.7x
SIGY Unlock Forecast - 30 Days FREE Trial $3M x x
SKIN Unlock Forecast - 30 Days FREE Trial $178M -1.8x 2.7x
SNOA Unlock Forecast - 30 Days FREE Trial $6M -5.6x 1.6x
SNWV Unlock Forecast - 30 Days FREE Trial $270M x -19.4x
SOLV Unlock Forecast - 30 Days FREE Trial $14392M 9.4x 2.9x
SRTS Unlock Forecast - 30 Days FREE Trial $63M 31.6x 1.2x
SSKN Unlock Forecast - 30 Days FREE Trial $7M -8.0x 5.7x
STIM Unlock Forecast - 30 Days FREE Trial $104M -1.0x 3.8x
STME Unlock Forecast - 30 Days FREE Trial $16M x x
STSS Unlock Forecast - 30 Days FREE Trial $74M -2.5x 0.2x
SYK Unlock Forecast - 30 Days FREE Trial $136856M 46.5x 11.7x
TCMD Unlock Forecast - 30 Days FREE Trial $621M 34.2x 3.0x
TELA Unlock Forecast - 30 Days FREE Trial $46M -1.8x 29.8x
TFX Unlock Forecast - 30 Days FREE Trial $5679M 31.0x 1.5x
TLSI Unlock Forecast - 30 Days FREE Trial $364M -3.6x -5.6x
TLSIW Unlock Forecast - 30 Days FREE Trial $72M x -1.9x
TMCI Unlock Forecast - 30 Days FREE Trial $177M -7.5x 2.0x
TNDM Unlock Forecast - 30 Days FREE Trial $1450M -17.1x 10.9x
TNON Unlock Forecast - 30 Days FREE Trial $10M -0.3x 2.1x
UFPT Unlock Forecast - 30 Days FREE Trial $1692M 25.2x 4.2x
USAQ Unlock Forecast - 30 Days FREE Trial $3M x x
UTMD Unlock Forecast - 30 Days FREE Trial $186M 16.0x 1.6x
VERO Unlock Forecast - 30 Days FREE Trial $3M 0.0x 1.3x
VYCO Unlock Forecast - 30 Days FREE Trial $5M x x
WST Unlock Forecast - 30 Days FREE Trial $19238M 39.1x 6.3x
XAIR Unlock Forecast - 30 Days FREE Trial $91M -0.3x 7.2x
XTNT Unlock Forecast - 30 Days FREE Trial $102M 58.0x 2.0x

Frequently Asked Questions - Axonics, Inc. Stock Forecast

How accurate are Axonics, Inc. stock predictions?

Our AI model shows a 26% Spearman correlation coefficient for AXNX predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Axonics, Inc. stock price forecasts?

Our analysis considers Axonics, Inc.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Axonics, Inc. a good investment in 2025?

Based on our AI analysis, Axonics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Axonics, Inc. forecasts updated?

Axonics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Axonics, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Axonics, Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...